Format
Sort by
Items per page

Send to

Choose Destination

Best matches for "Vortioxetine":

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Chen G et al. Clin Pharmacokinet. (2018)

Vortioxetine for depression in adults. Koesters M et al. Cochrane Database Syst Rev. (2017)

Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Sowa-Kućma M et al. Pharmacol Rep. (2017)

Search results

Items: 1 to 20 of 383

1.

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study.

Haro JM, Hammer-Helmich L, Saragoussi D, Ettrup A, Larsen KG.

Neuropsychiatr Dis Treat. 2019 Aug 13;15:2313-2323. doi: 10.2147/NDT.S206825. eCollection 2019.

2.

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population.

Miao J, Wang G, Hou J, Areberg J, Zhao Y, Højer AM, Ettrup A.

Adv Ther. 2019 Sep 24. doi: 10.1007/s12325-019-01092-4. [Epub ahead of print]

PMID:
31552551
3.

Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder.

Murthy NV, Xu R, Zhong W, Harvey PD.

J Affect Disord. 2019 Sep 4;260:550-556. doi: 10.1016/j.jad.2019.09.025. [Epub ahead of print]

4.

Applying the inclusion/exclusion criteria in placebo-controlled studies to a clinical sample: A comparison of medications.

Zimmerman M, Balling C, Chelminski I, Dalrymple K.

J Affect Disord. 2019 Sep 2;260:483-488. doi: 10.1016/j.jad.2019.09.012. [Epub ahead of print]

PMID:
31539683
5.

Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial.

Cao B, Park C, Rosenblat JD, Chen Y, Iacobucci M, Subramaniapillai M, Mansur RB, Zuckerman H, Lee Y, McIntyre RS.

J Psychopharmacol. 2019 Nov;33(11):1388-1394. doi: 10.1177/0269881119874485. Epub 2019 Sep 18.

PMID:
31530216
6.

Are early increases in physical activity a behavioral marker for successful antidepressant treatment?

Yun L, Fagan M, Subramaniapillai M, Lee Y, Park C, Mansur RB, McIntyre RS, Faulkner GEJ.

J Affect Disord. 2019 Sep 3;260:287-291. doi: 10.1016/j.jad.2019.09.002. [Epub ahead of print]

PMID:
31521865
7.

Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double-blind, placebo-controlled trial.

Seddighnia A, Tadayon Najafabadi B, Ghamari K, Noorbala AA, Ebrahimi Daryani N, Kashani L, Akhondzadeh S.

J Clin Pharm Ther. 2019 Sep 5. doi: 10.1111/jcpt.13032. [Epub ahead of print]

PMID:
31486103
8.

PVP-H2O2 Complex as a New Stressor for the Accelerated Oxidation Study of Pharmaceutical Solids.

Modhave D, Barrios B, Paudel A.

Pharmaceutics. 2019 Sep 3;11(9). pii: E457. doi: 10.3390/pharmaceutics11090457.

9.

Identification of potential drug name confusion errors in the Sentinel System.

Cocoros NM, Haynes K, Her Q, Cosgrove A, Dee E, Lin ND, Tu CM, Ding Y, Nguyen M, Toh S.

Pharmacoepidemiol Drug Saf. 2019 Sep 4. doi: 10.1002/pds.4891. [Epub ahead of print]

PMID:
31483085
10.

Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis.

He H, Xiang Y, Gao F, Bai L, Gao F, Fan Y, Lyu J, Ma X.

J Psychiatr Res. 2019 Nov;118:21-30. doi: 10.1016/j.jpsychires.2019.08.009. Epub 2019 Aug 16.

PMID:
31473564
11.

Vortioxetine use may cause false positive immunoassay results for urine methadone.

Uljon S, Kataria Y, Flood JG.

Clin Chim Acta. 2019 Aug 27;499:1-3. doi: 10.1016/j.cca.2019.08.026. [Epub ahead of print]

PMID:
31469980
12.

Vortioxetine Reduces Marble Burying but Only Transiently Enhances Social Interaction Preference in Adult Male BTBR T+Itpr3tf/J Mice.

Witt NA, Lee B, Ghent K, Zhang WQ, Pehrson AL, Sánchez C, Gould GG.

ACS Chem Neurosci. 2019 Oct 16;10(10):4319-4327. doi: 10.1021/acschemneuro.9b00386. Epub 2019 Sep 11.

PMID:
31468969
13.

Adapting the Goal Attainment Approach for Major Depressive Disorder.

McCue M, Parikh SV, Mucha L, Sarkey S, Cao C, Eramo A, Opler M, Webber-Lind B, François C.

Neurol Ther. 2019 Aug 21. doi: 10.1007/s40120-019-00151-w. [Epub ahead of print]

PMID:
31435869
14.

Restless Legs Syndrome Related to Vortioxetine: A Case Report.

Romigi A, Vitrani G, Caccamo M, Centonze D.

J Clin Psychopharmacol. 2019 Sep/Oct;39(5):514-516. doi: 10.1097/JCP.0000000000001092. No abstract available.

PMID:
31433340
15.

Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis.

Jacobson W, Zhong W, Nomikos GG, Christensen MC, Kurre Olsen C, Harvey PD.

Curr Med Res Opin. 2019 Aug 29:1-8. doi: 10.1080/03007995.2019.1657692. [Epub ahead of print]

PMID:
31422713
16.

Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial.

Jacobsen P, Zhong W, Nomikos G, Clayton A.

J Sex Med. 2019 Oct;16(10):1638-1649. doi: 10.1016/j.jsxm.2019.06.018. Epub 2019 Aug 9.

17.

Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.

Subramaniapillai M, Mansur RB, Zuckerman H, Park C, Lee Y, Iacobucci M, Cao B, Ho R, Lin K, Phan L, McIntyre RS.

Compr Psychiatry. 2019 Jul 24;94:152113. doi: 10.1016/j.comppsych.2019.07.006. [Epub ahead of print]

18.

Vortioxetine in the Treatment of Mood Disorders Associated with Burning Mouth Syndrome: Results of an Open-Label, Flexible-Dose Pilot Study.

Adamo D, Pecoraro G, Aria M, Favia G, Mignogna MD.

Pain Med. 2019 Jul 22. pii: pnz120. doi: 10.1093/pm/pnz120. [Epub ahead of print]

PMID:
31343684
19.

Vortioxetine treatment-emergent mania in the elderly: a case report.

D'Andrea G, De Ronchi D, Giaccotto L, Albert U.

Australas Psychiatry. 2019 Aug;27(4):413. doi: 10.1177/1039856219839471. No abstract available.

PMID:
31328985
20.

Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis.

Krause M, Gutsmiedl K, Bighelli I, Schneider-Thoma J, Chaimani A, Leucht S.

Eur Neuropsychopharmacol. 2019 Sep;29(9):1003-1022. doi: 10.1016/j.euroneuro.2019.07.130. Epub 2019 Jul 18. Review.

Supplemental Content

Loading ...
Support Center